Gilead Passes Two Phase III Test with HCV Pill
"Three down, one to go. Gilead Sciences met the main goals of two Phase III studies with its blockbuster hopeful sofosbuvir in patients with hepatitis C virus. The biopharma giant aims to use the results from the late-stage studies as part of a larger data package, which will go to the FDA later this year in the company's bid to advance the first all-oral attack on the liver-damaging disease."
To read more: Gilead passes two Phase III tests with key hep C pill - FierceBiotech http://www.fiercebiotech.com/story/gilead-passes-two-phase-iii-tests-key-hep-c-pill/2013-02-04#ixzz2JxOA6nir
1300 Wilson Boulevard | Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2013 Infectious Diseases Society of America